Clinical trials: Multi Vessel Coronary Artery Disease
Myocardial Infarction
Multicentre 2x2 Factorial Randomised Study Comparing Tirofiban Versus Abciximab and SES Versus BMS in AMI
The purpose of this study is to determine which from the four combinations tirofiban+sirolimus eluting stent (SES), tirofiban+bare metal stent (BMS), abciximab+SES, abciximab+BMS is the possible gold standard treatment for…
- Trial name
- NCT00229515
- Testing
- abciximab followed by implantation of bare metal stent, abciximab and Sirolimus eluting stent, tirofiban and bare metal stent
- Where
- Italy
- Volunteers
- 744 people
- Sponsor
- Marco Valgimigli
Coronary Artery Disease
Functional Lesion Assessment of Intermediate Stenosis to Guide Revascularisation
Narrowing of coronary arteries interferes with blood flow and can cause chest pain. But patients may have more than one narrowing and studies have shown that not all narrowings need to be treated.
- Trial name
- DEFINE-FLAIR (NCT02053038)
- Testing
- iFR, FFR
- Where
- 50 sites in United States, Australia and 15 more
- Volunteers
- 2,500 people
- Sponsor
- Imperial College London
Myocardial Infarction, Myocardial Ischemia
18F-fluorocholine PET-MR Imaging of Coronary Plaque Vulnerability
This study is designed as a prospective observational feasibility study. The investigators will study whether vulnerable plaques on OCT (fibrous cap ≤ 70 μm) show a locally increased uptake of 18F-choline on PET-MRI compared to…
- Conditions
- Myocardial Infarction, Myocardial Ischemia, Atherosclerosis, Coronary Artery Disease
- Trial name
- NCT03252990
- Testing
- PET-MRI, Optical Coherence Tomography
- Where
- Netherlands
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
Microvascular Coronary Artery Disease, STEMI
Clinical Trial for Evaluating the Effectiveness and Safety of Online caIMR in STEMI Patients
Despite the success of restoration of epicardial blood flow by the primary percutaneous coronary intervention (PPCI), approximately a half of patients with ST-segment elevation myocardial infarction (STEMI) have failed myocardial…
- Trial name
- FlashIV (NCT06118450)
- Testing
- Non-intervention
- Where
- 8 sites in China
- Volunteers
- 335 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
Coronary Artery Disease
First-in-man Trial Examining the Safety and Efficacy of BuMA Supreme and Resolute Integrity in Patients With de Novo Coronary Artery Stenosis
Prospective, multi-center, randomized 1:1, single blind trial using BuMA Supreme versus Resolute Integrity conducted in approximately 14 interventional cardiology centers in The Netherlands, Belgium, Spain and Portugal.
- Trial name
- NCT02236975
- Testing
- BuMA Supreme Biodegradable drug coating coronary stent system, Resolute Integrity durable polymer stent system
- Where
- 12 sites in Belgium, Netherlands and 2 more
- Volunteers
- 168 people
- Sponsor
- Sino Medical Sciences Technology Inc.
Coronary Artery Disease
Single-cell Multi-omics Analyses of OCT-diagnosed Plaque Subtypes in Coronary Artery Disease (MOOP-CAD)
The MOOP-CAD study program characterizes, for the first time, the pathophysiological processes and molecular mechanisms of coronary atherosclerotic plaque progression by combining in vivo intravascular imaging techniques with…
- Trial name
- MOOP-CAD (NCT06489119)
- Where
- 2 sites in China
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Harbin Medical University
Atherosclerosis, Coronary Artery Disease
A Prospective, Multi-center Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS Element™)
Compile acute (30-day) clinical outcomes data and 9-month angiographic and intravascular ultrasound (IVUS) data for the PROMUS Element™ Everolimus- Eluting Coronary Stent System in the treatment of patients with a single de novo…
- Trial name
- PLATINUM QCA (NCT00824434)
- Testing
- PROMUS Element™
- Where
- 17 sites in Australia, Malaysia and 2 more
- Volunteers
- 100 people
- Sponsor
- Boston Scientific Corporation
Anterior Wall Acute Myocardial Infarction
Evaluation of Intracoronary Hyperoxemic Oxygen Therapy in Anterior Acute Myocardial Infarction Patients (IC-HOT)
The primary objective of the study is to collect confirmatory data supporting the safety and effectiveness of SSO2 Therapy in treatment of anterior acute myocardial infarction (AMI) patients who have undergone successful…
- Trial name
- IC-HOT (NCT02603835)
- Testing
- SSO2 Therapy
- Where
- 15 sites in United States
- Volunteers
- 100 people
- Sponsor
- TherOx
Coronary Artery Disease
Deutsches Dual Therapy Stent Register
The DTS.DE registry is an initiative for the collection of high quality process and historical data of implantations with the COMBO Dual Therapy Stent in Germany.
- Trial name
- DTS Register (NCT02102997)
- Where
- Germany
- Volunteers
- 130 people
- Sponsor
- OrbusNeich
Coronary Artery Disease
Bioflow-DAPT Study
BIOFLOW-DAPT is a prospective, multi-center, international, two-arm randomized controlled clinical study. A total of 1'948 subjects will be randomized 1:1 to receive either Orsiro Mission or Resolute Onyx.
- Trial name
- NCT04137510
- Testing
- Percutaneous coronary intervention
- Where
- 53 sites in Australia, Austria and 16 more
- Volunteers
- 1,948 people
- Sponsor
- Biotronik AG
Coronary Arteriosclerosis
A Study To Evaluate the Effect of Rosuvastatin On Intravascular Ultrasound-Derived Coronary Atheroma Burden (ASTEROID)
The purpose of this study is to see if 40 mg of rosuvastatin taken daily will reduce the atherosclerosis (fatty deposits) in your arteries
- Trial name
- NCT00240318
- Testing
- Rosuvastatin calcium
- Where
- 61 sites in United States, Australia and 6 more
- Volunteers
- 450 people
- Sponsor
- AstraZeneca
Myocardial Infarction, Acute, Multi-Vessel Coronary Artery Stenosis
Timing of FFR-guided PCI for Non-IRA in STEMI and MVD (OPTION-STEMI)
Patients with STEMI (ST-segment elevation myocardial infarction) with multivessel disease which have PCI (percutaneous coronary intervention)-suitable non-IRA (infarct related artery) will be randomized to immediate complete…
- Trial name
- NCT04626882
- Testing
- Staged in-hospital or Immediate complete revascularization
- Where
- 14 sites in South Korea
- Volunteers
- 994 people
- Sponsor
- Chonnam National University Hospital
Coronary Heart Disease
CTCA Prior to Invasive Angiography in Post-Bypass Patients (BYPASS CTCA 2)
The goal of this clinical trial is to evaluate whether a coronary computed tomography angiography (CTCA)-guided strategy can reduce the risk of death, heart attack, stroke, and hospital admissions in patients experiencing angina…
- Trial name
- NCT07165678
- Testing
- CTCA
- Where
- United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- Queen Mary University of London
Chronic Stable Angina Pectoris
Outcome Research to Confirm the Anti-anginal Effect of T89 in Patients With Stable Angina
This is a multi-center, double-blind, randomized, placebo-controlled, parallel-group phase 3 clinical study to confirm the safety and efficacy of T89 in patients with stable angina pectoris, with an extended open-label period to…
- Trial name
- NCT03789552
- Testing
- T89 capsule
- Where
- United States
- Volunteers
- 765 people
- Sponsor
- Tasly Pharmaceuticals, Inc.
Coronary Artery Bypass Graft Surgery, Myocardial Ischemia
A Safety and Efficacy Study to Confirm the Cardioprotective Effects of MC-1 in Patients Undergoing High-Risk CABG
The purpose of this study is to determine the effect of MC-1 on the combined incidence of cardiovascular death and nonfatal myocardial infarction (MI) up to and including 30 days following coronary artery bypass graft (CABG)…
- Conditions
- Coronary Artery Bypass Graft Surgery, Myocardial Ischemia, Reperfusion Injury
- Trial name
- NCT00402506
- Testing
- (MC-1) Pyridoxal 5'-phosphate
- Where
- 2 sites in United States, Canada
- Volunteers
- 3,000 people
- Sponsor
- Medicure
NSTEMI - Non-ST Segment Elevation MI, Multi Vessel Coronary Artery Disease
Culprit Lesions in NSTEMI With Multi Vessel Disease (NSTEMI-CULPRIT)
Acute myocardial infarction owes to a plaque rupture resulting in total (STEMI) or partial occlusion (NSTEMI) of the coronary artery.
- Trial name
- NS-CULPRIT (NCT03479593)
- Testing
- CMR and OCT in NSTEMI patients with MVD
- Where
- Denmark
- Volunteers
- 100 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Coronary Atherosclerosis
Comparison of the Conor Sirolimus-eluting Coronary Stent to the Taxus Liberte Paclitaxel-eluting Coronary Stent in the Treatment of Coronary Artery Lesions
The purpose of this study is to evaluate the safety and effectiveness of the Conor Sirolimus-eluting Coronary Stent System in the treatment of coronary artery disease (a single atherosclerotic lesion) in native coronary arteries.
- Trial name
- NEVO RES-I (NCT00606333)
- Testing
- NEVO™ Sirolimus-eluting Coronary Stent System, Drug-eluting stent (TAXUS Liberte Paclitaxel-eluting Coronary Stent System)
- Where
- 2 sites in Brazil, New Zealand
- Volunteers
- 394 people
- Sponsor
- Cordis US Corp.
Coronary Artery Disease
The Stent or Surgery (SoS) Trial
This study compared two different methods of restoring blood flow to the heart when there has been a narrowing or blockage in the blood vessels that supply the heart.
- Trial name
- NCT00475449
- Testing
- percutaneous coronary intervention, coronary artery bypass grafting
- Volunteers
- 988 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Coronary Artery Disease, Coronary Stenosis
Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-VII: Sirolimus-eluting (Ultimaster) vs. Everolimus-Eluting Stents (Xience)
This study compares angiographic and clinical outcomes in patients with long coronary lesions treated with sirolimus-eluting stent (Ultimaster stent) or everolimus-eluting stent (Xience Alpine stent).
- Trial name
- LONG-DES VII (NCT03484234)
- Testing
- Ultimaster stent, Xience alpine stent
- Where
- 2 sites in South Korea
- Volunteers
- 36 people
- Sponsor
- Seung-Jung Park
Cardiovascular Events, MACE
Tezspire Cardiac Events PASS
The aim of this study is to evaluate the risk of serious adverse cardiovascular events in adolescent and adult patients with severe asthma taking tezepelumab compared to a population receiving standard of care treatment for…
- Trial name
- TRESPASS (NCT06951867)
- Testing
- Tezepelumab
- Where
- 4 sites in United States, Denmark and 2 more
- Volunteers
- 16,640 people
- Sponsor
- AstraZeneca